导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.76% | 2253/4772 |
| 近一周 | -0.17% | 911/5490 |
| 近一月 | -5.03% | 3330/5407 |
| 近一季 | -6.42% | 3493/5201 |
| 近半年 | -5.25% | 2686/4918 |
| 近一年 | 5.12% | 1739/4355 |
| 近两年 | 57.89% | 1241/2950 |
| 近三年 | 28.29% | 1098/2241 |
| 成立以来 | 74.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.43% 1796/4961 |
16.47% 1565/5312 |
- - |
- - |
| 2025 | 30.09% 1349/4813 |
3.10% 1191/3635 |
0.32% 2701/4076 |
27.06% 1315/4524 |
-1.02% 2783/4813 |
| 2024 | 6.97% 1705/3463 |
-3.70% 1545/2808 |
-1.14% 948/3014 |
14.16% 2038/3129 |
-1.57% 1751/3463 |
| 2023 | -16.60% 1689/2656 |
5.34% 794/2280 |
-6.30% 1618/2385 |
-10.10% 1951/2515 |
-6.01% 1591/2655 |
| 2022 | -24.37% 1212/2207 |
-17.42% 1208/1919 |
8.63% 344/2016 |
-15.53% 1311/2113 |
-0.20% 1574/2208 |
| 2021 | 9.84% 449/1822 |
-5.40% 922/1255 |
12.70% 317/1330 |
-2.96% 605/1466 |
6.16% 229/1822 |
| 2020 | 44.86% 224/1250 |
-1.67% 228/1028 |
22.35% 209/1067 |
9.29% 658/1164 |
10.16% 611/1184 |
| 2019 | - - |
- - |
- - |
- - |
9.82% 187/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 申万菱信中小企业100指数(LOF)C VS. 长安沪深300非周期A(740101) |